Arjen Joosse

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. doi Gender differences in melanoma survival: female patients have a decreased risk of metastasis
    Arjen Joosse
    Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands
    J Invest Dermatol 131:719-26. 2011
  2. doi Reactive oxygen species and melanoma: an explanation for gender differences in survival?
    Arjen Joosse
    Department of Public Health, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Pigment Cell Melanoma Res 23:352-64. 2010
  3. doi Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials
    Arjen Joosse
    Erasmus University Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 31:2337-46. 2013
  4. doi Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials
    Arjen Joosse
    Department of Public Health, Erasmus University Medical Center, PO Box 2040 3000 CA, Rotterdam, The Netherlands
    J Clin Oncol 30:2240-7. 2012

Detail Information

Publications4

  1. doi Gender differences in melanoma survival: female patients have a decreased risk of metastasis
    Arjen Joosse
    Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands
    J Invest Dermatol 131:719-26. 2011
    ..Localized melanomas in women had a lower propensity to metastasize, resulting in a better survival when compared with men, even after first disease progression. These results suggest differences in tumor-host interaction across gender...
  2. doi Reactive oxygen species and melanoma: an explanation for gender differences in survival?
    Arjen Joosse
    Department of Public Health, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Pigment Cell Melanoma Res 23:352-64. 2010
    ..Therefore, ROS may explain the observed differences between males and females in melanoma survival...
  3. doi Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials
    Arjen Joosse
    Erasmus University Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 31:2337-46. 2013
    ..To study sex differences in survival and progression in patients with stage III or IV metastatic melanoma and to compare our results with published literature...
  4. doi Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials
    Arjen Joosse
    Department of Public Health, Erasmus University Medical Center, PO Box 2040 3000 CA, Rotterdam, The Netherlands
    J Clin Oncol 30:2240-7. 2012
    ....